Elafibranor (2) – Iqirvo®
Primary biliary cholangitis (in combination with ursodeoxycholic acid)
Characteristics
| Start date | 15.11.2026 |
|---|---|
| Resolution | 05.05.2027 – active procedure |
| INN | Elafibranor |
| Brand name | Iqirvo® |
| Pharm. company | Ipsen Pharma GmbH |
| G-BA Procedure ID | D-1398 |
| Therapeutic area | n.d. Orphan (turnover limit) |
| Reason for procedure | Reassessment: Orphan turnover exceeded |
Associated procedures
| Elafibranor (2) | Iqirvo® | Ipsen Pharma GmbH | Primary biliary cholangitis (in combination with ursodeoxycholic acid) | n.d. | active procedure Orphan (turnover limit) | |
| Elafibranor (1) | Iqirvo® | Ipsen Pharma GmbH | Primary biliary cholangitis (combination with ursodeoxycholic acid) | 6,000–13,000 | 100% Hint for minor additional benefit Orphan |
<< List of all resolutions